CoronaryAtlas logo
CoronaryAtlas
Cytochrome P450 2C19
Pathway / Platelet adhesion & activation

Cytochrome P450 2C19

CYP2C19gene

CYP2C19 genetic variants regulate clopidogrel activation, modulating platelet aggregation inhibition and stent thrombosis risk after coronary intervention.

Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleMetabolizes clopidogrel to active inhibitor; mediates platelet P2Y12-receptor antagonism and thrombus prevention.
Also acts inThromboxane / COX-1
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000165841

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
85
C — confounder / Type-II
63
A — assay feasibility
52
E — evidence strength
32
T1DI (composite)
10
Specificity differential (R−C)+21.6
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable

Human genetic evidence

0.007
Open Targets association (NSTEMI)

Literature evidence(3)

Clinical trials(8)